Inhibrx to Present New Clinical Data at Three Meetings
The biopharmaceutical company will reveal clinical and survival findings for its cancer therapies at upcoming international summits.
Updated on Oct. 13, 2026 in Cancer
Inhibrx Biosciences is scheduled to present new clinical, efficacy, and survival data at three scientific conferences held in Madrid, Miami, and Seoul. These presentations begin October 25, 2026, and will offer updated insights into the company's research portfolio.
Why it matters
Scientific conferences serve as vital venues for validating clinical research, allowing the broader medical community to evaluate new data on emerging treatment efficacy. Sharing these findings helps oncologists and researchers track the development trajectory of investigational therapies.
Inhibrx Biosciences will disclose findings from its clinical-stage research, including survival and efficacy data, across three independent scientific forums. These results remain preliminary pending formal presentation at the upcoming professional congresses.
The players
Inhibrx Biosciences
A clinical-stage biopharmaceutical company focused on the development of novel therapeutic candidates for cancer.
The details
The presentations will detail the progression of Inhibrx Biosciences' clinical-stage pipeline as researchers analyze study results for potential therapeutic impacts in oncology. By sharing these findings in peer-reviewed environments like ESMO, MSTS, and CTOS, the company provides data that allows specialists to assess the safety and efficacy of its experimental approach. Updated survival statistics and efficacy outcomes will be made accessible to the public via the company website following the events.
Timeline
October 25, 2026: Oral presentation at the ESMO Congress in Madrid, Spain.
October 29, 2026: Oral presentation at the MSTS Annual Meeting in Miami, Florida.
November 19-20, 2026: Poster and oral presentations at the CTOS Annual Meeting in Seoul, South Korea.
Health Landscape
The release of this data occurs within the structured cycle of global oncology meetings like the ESMO Congress, which serve as the primary venues for peer-vetted research communication. This process ensures that new clinical-stage developments are reviewed by the wider scientific community.
The findings presented at these meetings will clarify the status of research that may eventually inform future treatment options for patients. If you are tracking the progress of specific cancer research, discussing the outcomes of these studies with your oncologist is a constructive step.
The takeaway
Clinical trial updates are essential for understanding the potential viability of emerging cancer therapies as they progress through development stages. Following the disclosures from international meetings helps patients and caregivers maintain a clear view of current research trends in oncology.
Further reading
For more on developments in oncology research, visit our Cancer section.
More information
View the complete schedule and upcoming disclosures on the Inhibrx investor events and presentations page.
